期刊文献+

IL-33和sST2联合MELD评分对乙型肝炎相关慢加急性/亚急性肝衰竭患者短期预后的预测价值 被引量:3

Value of IL-33 and sST2 combined with MELD score in predicting short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure
原文传递
导出
摘要 目的探讨IL-33和可溶性生长刺激表达基因2蛋白(sST2)联合终末期肝病模型(MELD)评分对乙型肝炎相关慢加急性(亚急性)肝衰竭(HBV-ACLF)患者短期预后的预测价值。方法检测HBV-ACLF患者59例(观察组)和健康志愿者30例(对照组)生化指标、IL-33和sST2,计算MELD评分。根据HBV-ACLF患者入院后第12周的病情分为好转组31例及恶化组28例,比较两组相关指标,采用二元logistic回归分析HBV-ACLF患者短期预后的影响因素,采用ROC曲线评估IL-33、sST2及MELD评分对HBV-ACLF患者短期预后的预测价值。结果与对照组比较,观察组TBil、国际标准化比值(INR)、凝血酶原时间(PT)、空腹血糖、IL-33、sST2和MELD评分升高(P<0.05),好转组PT、INR、IL-33、sST2、TBil和MELD评分较恶化组降低(P<0.05)。高水平IL-33和sST2以及高MELD评分是HBV-ACLF患者短期预后的独立危险因素(P<0.05)。ROC曲线分析显示,MELD评分、IL-33和sST2预测HBV-ACLF患者短期预后的AUC分别为0.816、0.810和0.729,IL-33+sST2和IL-33+sST2+MELD评分预测预后的AUC分别为0.847和0.851。取IL-33+sST2+MELD评分的最佳截断值为0.491时,其预测HBV-ACLF患者预后的灵敏度为0.786,特异度为0.839。结论IL-33和sST2对HBV-ACLF患者短期预后有较好的预测价值,其联合MLED评分的预测效果更好。 Objective To investigate the value of IL-33 and soluble growth stimulation expressed gene 2(sST2)combined with model for end-stage liver diseases(MELD)score in predicting short-term prognosis of the patients with hepatitis B virus-related acute-on-chronic liver failure(HBV-ACLF).Methods The biochemical indexes,IL-33 and sST2 were detected in 59 HBVACLF patients(group A)and 30 healthy people(group B).MELD score was calculated.The HBVACLF patients were divided into two groups of A1(getting better)and A2(getting exacerbated)according to the illness status in the 12 t h week after admission.The indicators were compared between the two groups.The influencing factors for the short-term prognosis of the patients with HBV-ACLF were analyzed.The predictive values of IL-33,sST2 and MELD score were anaylzed by ROC curve.Results Compared to group B,the TBil,international normalized ratio(INR),prothrombin time(PT),fasting blood glucose,IL-33,sST2 and MELD score were higher in group A(P<0.05).The PT,INR,IL-33,sST2,TBil and MELD score were lower in group A1 than those in group A2(P<0.05).The higher levels of IL-33,sST2 and MELD score were the risk factors for the short-term prognosis of the patients with HBV-ACLF(P<0.05).ROC curve analysis showed that the AUC of MELD score,IL-33 and sST2 in predicting the short-term prognosis of HBV-ACLF patients were0.816,0.810 and 0.729,respectively.The AUC of IL-33+sST2 and IL-33+sST2+MELD score in predicting the short-term prognosis were 0.847 and 0.851,respectively.When the cut-off value of IL-33+sST2+MELD score was 0.491,the sensitivity and specificity of predicting the prognosis of HBV-ACLF patients were 0.786 and 0.839,respectively.Conclusion IL-33 and sST2 have higher predictive value for the short-term prognosis of the patients with HBV-ACLF,which combined with MLED score have better predictive efficiency.
作者 明芳 章颖 李兆明 刘先进 薛红 MING Fang;ZHANG Ying;LI Zhaoming(Department of Intensive Infectious Diseases,Affiliated Nantong Third Hospital,Nantong University,Nantong 226001,CHINA)
出处 《江苏医药》 CAS 2022年第2期186-190,共5页 Jiangsu Medical Journal
基金 南通市市级科技计划项目(MSZ18196) 南通市市级科技计划项目(MSZ20099)。
关键词 白细胞介素33 可溶性生长刺激表达基因2蛋白 终末期肝病模型 慢加急性(亚急性)肝衰竭 预后 Interleukin-33 Soluble growth stimulation expressed gene 2 Model for endstage liver disease Hepatitis B virus-related acute-on-chronic liver failure Prognosis
  • 相关文献

参考文献6

二级参考文献40

  • 1陈瑞玲,罗瑞虹,崇雨田,吴元凯,赵志新,高志良.MELD评分对慢性重型乙型病毒性肝炎患者短期预后评价的价值[J].中山大学学报(医学科学版),2006,27(5):594-596. 被引量:19
  • 2钱志平,廖粤斌,王介非,巫善明.MELD评分对慢性乙型重型肝炎患者预后的评价作用[J].肝脏,2006,11(5):316-317. 被引量:12
  • 3钦伦秀,任宁.原发性肝癌的外科治疗[J].中华肿瘤防治杂志,2006,13(24). 被引量:17
  • 4Bruix J, Sherman M. Management of hepatocellular carcinoma: an update [ J ]. Hepatology ( Baltimore, Md ), 2011, 53 ( 3 ) : 1020-1022.
  • 5Schneider PD. Preoperative assessment of liver function [ J ]. The Surgical Clinics of North America, 2004,84(2) :355-373.
  • 6Pagliaro L. MELD: the end of Child-Pugh classification? [ J]. Journal of Hepatology, 2002,36( 1 ) :141-142.
  • 7Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease [ J ]. Hepatology (Baltimore, Md), 2001,33(2) :464-470.
  • 8Biggins SW, Bambha K. MELD-based liver allocation: who is un-derserved? [ J ]. Seminars in Liver Disease, 2006, 26 ( 3 ) : 211-220.
  • 9Brown RS, Jr. , Lake JR. The survival impact of liver transplanta- tion in the MELD era, and the future for organ allocation and dis- tribution [ J ]. Am J Transplant, 2005,5 ( 2 ) :203-204.
  • 10Northup PG, Wananmker RC, Lee VD, et al. Model for End- Stage Liver Disease (MELD) predicts nontransplant surgical mor- tality in patients with cirrhosis [ J ]. Ann Surg, 2005,242 ( 2 ) : 244 -251.

共引文献553

同被引文献36

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部